Clinical Trials Logo

Drug-Induced Acute Liver Injury clinical trials

View clinical trials related to Drug-Induced Acute Liver Injury.

Filter by:
  • None
  • Page 1

NCT ID: NCT05711459 Recruiting - Clinical trials for Drug-Induced Acute Liver Injury

Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

The clinical trial is designed to evaluate the efficacy of bicyclol for patients with antineoplastic drug-induced liver injury and investigate factors effecting the therapeutic outcome.

NCT ID: NCT05063500 Recruiting - Clinical trials for Drug-Induced Acute Liver Injury

The Multi-Center, Randomized, Double-blind, Positive Controlled Clinical Trial of Bicyclol in the Treatment of Acute DILI

Start date: December 20, 2021
Phase: Phase 3
Study type: Interventional

The study adopted the design of multi-center, randomized, double-blind, positive control drug, superiority test, using the double-blind double-simulating skills. The qualified subjects, according to the ratio of 1:1, were randomized into experimental group and positive drug control group and received a treatment course of 4 weeks, all individuals were followed up for 4 weeks after drug withdrawal.

NCT ID: NCT03679442 Completed - Clinical trials for Drug-Induced Acute Liver Injury

Macrophage Markers, Soluble CD163 (sCD163) and Soluble CD206 (sCD206) in Paracetamol Overdose

Start date: September 8, 2014
Phase: Phase 1
Study type: Interventional

Paracetamol (PCM) is a widely used over-the-counter analgesic, and overdose with PCM is a condition regularly seen in everyday clinical practice. Identification of the patients with early signs of liver injury that may develop into acute liver failure is important. Previous research has shown that macrophages play a role in the development of liver damage in PCM-induced acute liver failure, making macrophage markers interesting possible biomarkers of this condition. In the present study, the investigators aimed to investigate the extent and timing of macrophage activation in PCM-induced liver injury by measuring levels of macrophage markers sCD163 and sCD206 in patients admitted with PCM overdose. The investigators also hoped to find out whether these markers are valuable as prognostic markers of severe outcome in these patients. Furthermore the investigators examined the possible effect of antidote treatment with N-acetylcysteine on activation and function of macrophages by administering NAC to healthy subjects and measuring levels of sCD163 and sCD206 prior to and after completion of treatment.

NCT ID: NCT02944552 Completed - Clinical trials for Drug-Induced Acute Liver Injury

The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI

Start date: August 18, 2017
Phase: Phase 2
Study type: Interventional

The study adopted the superiority design of multi center, randomized, double-blind, positive control drug, dose finding, using two simulation skills. The qualified subjects, according to the ratio of 1:1:1, were randomized into low dose group, high dose group and positive drug control group, and received a treatment course of 4-8 weeks, all individuals were followed up for 4 weeks after drug withdrawal.